New cocktail aims to tame incurable head and neck cancer

NCT ID NCT02270814

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a three-drug combination called CACTUX (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants have advanced or recurrent cancer that cannot be removed by surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE HEAD AND NECK HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Sanford Cancer Center Oncology Clinic and Pharmacy

Sioux Falls, South Dakota, 57104, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.